Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) study

Journal of the American Society of Nephrology

Volumn 18, Issue 3, 2007, Pages 975-984

  Coyne, Daniel W ^a   Kapoian, Toros ^b   Suki, Wadi ^c   Singh, Ajay K ^d   Moran, John E ^e   Dahl, Naomi V ^c   Rizkala, Adel R ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c Kidney Institute Inc ^*  (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e University of Minnesota   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC GLUCONATE; FERRITIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; AGED; ANEMIA; ARTERY OCCLUSION; ARTICLE; BACKACHE; BACTERIAL INFECTION; BLOOD CLOTTING DISORDER; BLOOD DISEASE; BRONCHITIS; CARDIOPULMONARY INSUFFICIENCY; CELLULITIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DYSPEPSIA; DYSPNEA; ENDOCARDITIS; FEMALE; FERRITIN BLOOD LEVEL; FURUNCULOSIS; GANGRENE; HEART ARREST; HEART ARRHYTHMIA; HEART DISEASE; HEART INFARCTION; HEMATOMA; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPOTENSION; INFECTION; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; OPEN STUDY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE HEMOGLOBIN CONTENT; RHINOPHARYNGITIS; SEPSIS; SKIN INFECTION; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VASCULAR DISEASE;

EID: 33947212276     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006091034     Document Type: Article

References (32)

1. IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis 37: S182-S238, 2001
2. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 30: S192-S240, 1997
3. Coyne DW: Iron indices: What do they really mean? Kidney Int 101: S4-S8, 2006
4. Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK: The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 7: 2654-2657, 1996
5. Lin JL, Chang MY, Tan DT, Leu ML: Short-term small-dose intravenous iron trial to detect functional iron deficiency in dialysis patients. Am J Nephrol 21: 91-97, 2001
6. Mittman N, Sreedhara R, Mushnick R, Chattopadhyay J, Zelmanovic D, Vaseghi M, Avram MM: Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis 30: 912-922, 1997
7. Tessitore N, Solero GP, Lippi G, Bassi A, Faccini GB, Bedogna V, Gammaro L, Brocco G, Restivo G, Bernich P, Lupo A, Maschio G: The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 16: 1416-1423, 2001
8. US Renal Data System: USRDS 2004 Annual Data Report: Atlas of End Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004
9. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47: S11-S145, 2006
10. Centers for Medicaid & Medicare Services: 2005 Annual Report, End Stage Renal Disease Clinical Performance Measures Project. Am J Kidney Dis 48[Suppl 2]: S1-S106, 2006
11. Centers for Medicaid & Medicare Services: 2002 Annual Report, End Stage Renal Disease Clinical Performance Measures Project. Am J Kidney Dis 42[Suppl 2]: S1-S96, 2003
12. Aronoff GR: Safety of intravenous iron in clinical practice: Implications for anemia management protocols. J Am Soc Nephrol 15[Suppl]: S99-S106, 2004
13. Fishbane S: Iron treatment: Impact of safety issues. Am J Kidney Dis 32: S152-S156, 1998
14. Van Wyck DB, Bailie G, Aronoff G: Just the FAQs: Frequently asked questions about iron and anemia in patients with chronic kidney disease. Am J Kidney Dis 39: 426-432, 2002
15. Chuang CL, Liu RS, Wei YH, Huang TP, Tarng DC: Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol Dial Transplant 18: 370-377, 2003
16. Fudin R, Jaichenko J, Shostak A, Bennett M, Gotloib L: Correction of uremic iron deficiency anemia in hemodialyzed patients: A prospective study. Nephron 79: 299-305, 1998
17. Feelders RA, Vreugdenhil G, Eggermont AM, Kuiper-Kramer PA, van Eijk HG, Swaak AJ: Regulation of iron metabolism in the acute-phase response: Interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients. Eur J Clin Invest 28: 520-527, 1998
18. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448-454, 1999
19. Fishbane S, Shapiro W, Dutka P, Valenzuela OF, Faubert J: A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 60: 2406-2411, 2001
20. Coyne DW, Adkinson NF, Nissenson AR, Fishbane S, Agarwal R, Eschbach JW, Michael B, Folkert V, Batlle D, Trout JR, Dahl N, Myirski P, Strobos J, Warnock DG: Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int 63: 217-224, 2003
21. Michael B, Coyne DW, Folkert VW, Dahl NV, Warnock DG: Sodium ferric gluconate complex in haemodialysis patients: A prospective evaluation of long-term safety. Nephrol Dial Transplant 19: 1576-1580, 2004
22. Michael B, Coyne DW, Fishbane S, Folkert V, Lynn R, Nissenson AR, Agarwal R, Eschbach JW, Fadem SZ, Trout JR, Strobos J, Warnock DG: Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int 61: 1830-1839, 2002
23. Michael B: The safety of sodium ferric gluconate complex in haemodialysis patients has been extensively evaluated. Nephrol Dial Transplant 20: 1770, 2005
24. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG: Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16: 3070-3080, 2005
25. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998
26. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006
27. Guyader D, Jacquelinet C, Moirand R, Turlin B, Mendler MH, Chaperon J, David V, Brissot P, Adams P, Deugnier Y: Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 115: 929-936, 1998
28. Morrison ED, Brandhagen DJ, Phatak PD, Barton JC, Krawitt EL, El-Serag HB, Gordon SC, Galan MV, Tung BY, Ioannou GN, Kowdley KV: Serum ferritin level predicts advanced hepatic fibrosis among US patients with phenotypic hemochromatosis. Ann Intern Med 138: 627-633, 2003
29. Admas PC, Deugnier Y, Moirand R, Brissot P: The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 25: 162-166, 1997
30. Crawford DH, Jazwinska EC, Cullen LM, Powell LW: Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation. Gastroenterology 114: 1003-1008, 1998
31. Tavill AS: Diagnosis and management of hemochromatosis. Hepatology 33: 1321-1328, 2006
32. Weiss G, Goodnough LT: Anemia of chronic disease. N Engl J Med 352: 1011-1023, 2005